Atara Biotherapeutics (NASDAQ:ATRA) Raised to Strong-Buy at RODMAN&RENSHAW

Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by research analysts at RODMAN&RENSHAW to a “strong-buy” rating in a report issued on Friday,Zacks.com reports.

A number of other research firms also recently weighed in on ATRA. Canaccord Genuity Group lifted their target price on Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a research report on Friday. They set a “buy” rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Atara Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.75.

Atara Biotherapeutics Stock Performance

Shares of ATRA stock opened at $11.40 on Friday. Atara Biotherapeutics has a 52 week low of $6.50 and a 52 week high of $39.50. The company has a market capitalization of $65.66 million, a price-to-earnings ratio of -0.44 and a beta of 0.55. The company has a 50-day simple moving average of $10.80 and a 200 day simple moving average of $9.60.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating the consensus estimate of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same period in the previous year, the company posted ($16.50) EPS. Sell-side analysts forecast that Atara Biotherapeutics will post -12.12 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ATRA. Vestal Point Capital LP boosted its holdings in shares of Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 12,677 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Atara Biotherapeutics by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after buying an additional 4,043 shares during the last quarter. FMR LLC boosted its stake in Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 7,381 shares in the last quarter. State Street Corp grew its position in Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in Atara Biotherapeutics during the second quarter worth about $79,000. 70.90% of the stock is owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.